RecruitingPhase 2NCT07467772
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Studying Endometrial stromal sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Intervention
- Elacestrant(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2026 – 2028
Study locations (2)
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Stemline Therapeutics, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07467772 on ClinicalTrials.govOther trials for Endometrial stromal sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT03624244Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)Centre Leon Berard
- RECRUITINGNCT00005095Specimen and Data Study for Ovarian Cancer Early Detection and PreventionNorthwestern University